Related references
Note: Only part of the references are listed.Extracellular vesicle-mediated bone metabolism in the bone microenvironment
Qi Li et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2018)
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma
Andrew J. Yee et al.
FUTURE ONCOLOGY (2018)
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
Noopur Raje et al.
LANCET ONCOLOGY (2018)
Biology and treatment of myeloma related bone disease
Evangelos Terpos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
The Proteasome and Myeloma-Associated Bone Disease
Fabrizio Accardi et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis
Manoj K. Pandey et al.
EXPERIMENTAL HEMATOLOGY (2017)
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts
Marina Bolzoni et al.
HAEMATOLOGICA (2017)
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease
Oi Lin Lee et al.
INTERNAL MEDICINE JOURNAL (2017)
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells
A. Ray et al.
LEUKEMIA (2017)
Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects
Haiming Chen et al.
MOLECULAR CANCER RESEARCH (2017)
Emerging treatment approaches for myeloma-related bone disease
Maria Gavriatopoulou et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
Federica Costa et al.
ONCOTARGET (2017)
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts
Marina Bolzoni et al.
HAEMATOLOGICA (2017)
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20
B. Dalla Palma et al.
LEUKEMIA (2016)
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
R. H. Prabhala et al.
LEUKEMIA (2016)
Blocking the ZZ domain of sequestosome 1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo
J. Teramachi et al.
LEUKEMIA (2016)
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
Gang An et al.
BLOOD (2016)
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
Jesus Delgado-Calle et al.
CANCER RESEARCH (2016)
Revisiting IL-6 antagonism in multiple myeloma
Thomas Matthes et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Current Controversies in the Management of Myeloma Bone Disease
Rebecca Silbermann et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Characterization of Regulatory Extracellular Vesicles from Osteoclasts
N. Huynh et al.
JOURNAL OF DENTAL RESEARCH (2016)
Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation
Defang Li et al.
NATURE COMMUNICATIONS (2016)
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
N. Raje et al.
BLOOD CANCER JOURNAL (2016)
Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity
Weijia Sun et al.
CELL DISCOVERY (2016)
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis
Jin Kyun Park et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Osteoblast-derived microvesicles: A novel mechanism for communication between osteoblasts and osteoclasts
Lili Deng et al.
BONE (2015)
Matrix vesicles: Are they anchored exosomes?
Irving M. Shapiro et al.
BONE (2015)
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
Adel Ersek et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Primary transcripts of microRNAs encode regulatory peptidesPrimary transcripts of microRNAs encode regulatory peptides
Dominique Lauressergues et al.
NATURE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
Maria Rita Pitari et al.
ONCOTARGET (2015)
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation
Lavinia Raimondi et al.
ONCOTARGET (2015)
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
Robert Z. Orlowski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study
V. Petitprez et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
The proportion of CD16+CD14dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma
Anne M. Sponaas et al.
IMMUNITY INFLAMMATION AND DISEASE (2015)
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Jesus San-Miguel et al.
BLOOD (2014)
The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss
Masahiro Shinohara et al.
BONE (2014)
Sotatercept in patients with osteolytic lesions of multiple myeloma
Kudrat M. Abdulkadyrov et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis
B. Frediani et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma
R. Silbermann et al.
LEUKEMIA (2014)
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
H. Eda et al.
LEUKEMIA (2014)
Therapeutic targeting of microRNAs: current status and future challenges
Zhonghan Li et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Management of bone disease in multiple myeloma
Evangelos Terpos et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease
Giacomina Brunetti et al.
ONCOTARGET (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Gareth J. Morgan et al.
CLINICAL CANCER RESEARCH (2013)
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules
Marina Bolzoni et al.
EXPERIMENTAL HEMATOLOGY (2013)
Immunology and bone
Lynett Danks et al.
JOURNAL OF BIOCHEMISTRY (2013)
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease
Marco Rossi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation
T. Kagiya et al.
JOURNAL OF PERIODONTAL RESEARCH (2013)
Monocyte Exosomes Stimulate the Osteogenic Gene Expression of Mesenchymal Stem Cells
Karin Ekstrom et al.
PLOS ONE (2013)
Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes
Ji Fang et al.
APOPTOSIS (2012)
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2012)
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton et al.
EUROPEAN JOURNAL OF CANCER (2012)
Interferon-β-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF
Jun Zhang et al.
FEBS LETTERS (2012)
The stimulation of an osteogenic response by classical monocyte activation
M. Omar Omar et al.
BIOMATERIALS (2011)
MicroRNA-210 Regulates Cancer Cell Proliferation through Targeting Fibroblast Growth Factor Receptor-like 1 (FGFRL1)
Soken Tsuchiya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
S. Vallet et al.
LEUKEMIA (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma
Kimberly Noonan et al.
BLOOD (2010)
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Rao H. Prabhala et al.
BLOOD (2010)
Advances in the understanding of myeloma bone disease and tumour growth
Shmuel Yaccoby
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CD16 (FcR gamma III) as a potential marker of osteoclast precursors in psoriatic arthritis
Yahui Grace Chiu et al.
ARTHRITIS RESEARCH & THERAPY (2010)
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
Ravi Vij et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation
Yuko Hiruma et al.
BLOOD (2009)
Impaired Micro-RNA Pathways Diminish Osteoclast Differentiation and Function
Toshifumi Sugatani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210
Pasquale Fasanaro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women
Jon Ruckle et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
Paul J. Kostenuik et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Proteasome Inhibitors Impair RANKL-Induced NF-κB Activity in Osteoclast-Like Cells Via Disruption of p62, TRAF6, CYLD, and IκBα Signaling Cascades
Estabelle Ang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients
S. Colucci et al.
LEUKEMIA (2009)
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6
Huang Hongming et al.
LEUKEMIA RESEARCH (2009)
Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma
Kavita M. Dhodapkar et al.
BLOOD (2008)
CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions
Nicola Giuliani et al.
CANCER RESEARCH (2008)
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals
Masahiro Shinohara et al.
CELL (2008)
The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation
Seoung Hoon Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I. Breitkreutz et al.
LEUKEMIA (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides
Ann T. Poblenz et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
MicroRNA-223 is a key factor in osteoclast differentiation
T. Sugatani et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
The molecular understanding of osteoclast differentiation
Masataka Asagiri et al.
BONE (2007)
The CD14+CD16+blood monocytes: their role in infection and inflammation
Loems Ziegler-Heitbrock
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis
H. Chen et al.
ONCOGENE (2006)
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients
N Giuliani et al.
BLOOD (2006)
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
LA Ehrlich et al.
BLOOD (2005)
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function
I Zavrski et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
JW Lee et al.
BLOOD (2004)
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction
S Colucci et al.
BLOOD (2004)
Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α-induced osteoclastogenesis in vivo
H Kitaura et al.
JOURNAL OF IMMUNOLOGY (2004)
Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
BO Oyajobi et al.
BLOOD (2003)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes:: a potential role in multiple myeloma bone disease
N Giuliani et al.
BLOOD (2002)
Role of the bone marrow microenvironment in multiple myeloma
GD Roodman
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Distinct molecular mechanism for initiating TRAF6 signalling
H Ye et al.
NATURE (2002)
Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease
SJ Choi et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
RN Pearse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand
JH Han et al.
BLOOD (2001)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Share Paper
